Cartesian Therapeutics (NASDAQ: RNAC) posts Q2 profit, extends cash runway into 2028
Rhea-AI Filing Summary
Cartesian Therapeutics, Inc. reported results for the quarter ended June 30, 2026, while advancing multiple clinical programs for its lead CAR-T candidate Descartes-08 in autoimmune diseases. The Phase 3 AURORA trial in generalized myasthenia gravis is enrolling about 100 patients, with top-line data expected in 1Q27 and a planned BLA filing in mid-2027.
The company is also running the Phase 2 TRITON trial in myositis, with subset data expected in 1H27 to guide a potential pivotal trial, and the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis and other autoimmune diseases, with data expected in 1H27. A new strategic licensing agreement with WestGene supports an in vivo CAR-T platform; a Phase 1 MG trial using targeted lipid nanoparticles is expected to start in 2H26, with in-human data in 1H27.
Liquidity is supported by approximately $149.3 million in cash, cash equivalents and restricted cash as of June 30, 2026 and a credit facility with K2 HealthVentures providing up to $150 million in non-dilutive financing, including an initial $50 million term loan funded in May 2026. The company expects these resources to fund planned operations into 2028. For the quarter, net income was $15.8 million, or $0.47 basic net income per share, with research and development expenses of $20.4 million and general and administrative expenses of $8.7 million.
Positive
- None.
Negative
- None.
Filing Explained
Only 50 million dollars of the up-to-150-million-dollar facility was funded by June 30, 2026; more shares reduce holders’ percentage ownership absent offsets.
The company had funded
The release characterizes up to
The remaining facility capacity therefore remains unresolved; the filing identifies draw windows beginning in 2027 and 2028, with the specified milestones determining whether the two scheduled tranches become available.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash, cash equivalents and restricted cash: $149.3 million
K2HV credit facility capacity: Up to $150 million
Research and development expense: $20.4 million
+5 more
8 metrics
Cash, cash equivalents and restricted cash
$149.3 million
As of June 30, 2026, expected to fund operations into 2028
K2HV credit facility capacity
Up to $150 million
Non-dilutive financing, including an initial $50 million term loan funded in May 2026
Research and development expense
$20.4 million
Three months ended June 30, 2026
General and administrative expense
$8.7 million
Three months ended June 30, 2026
Net income
$15.8 million
Three months ended June 30, 2026
Basic net income per share
$0.47
Three months ended June 30, 2026, allocable to common stockholders
AURORA Phase 3 sample size
Approximately 100 patients
Randomized MG trial of Descartes-08 vs placebo
Expected key readouts
Four
Clinical data readouts expected before or during 2027 across Descartes-08 programs
Key Terms
contingent value rights liability, Bayesian Optimal Interval (BOIN) adaptive design, Regenerative Medicine Advanced Therapy Designation, Rare Pediatric Disease Designation, +1 more
5 terms
contingent value rights liability financial
"Contingent value rights liability | 356,700 | | | 392,100"
Bayesian Optimal Interval (BOIN) adaptive design technical
"dose levels using a Bayesian Optimal Interval (BOIN) adaptive design"
Regenerative Medicine Advanced Therapy Designation regulatory
"has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation"
A U.S. regulatory designation that expedites development and review of certain cell, gene and tissue-based therapies designed to repair, replace or restore damaged tissue or organ function. It matters to investors because receiving the designation can shorten the path to approval, increase interaction with regulators, and make a program more attractive to partners or buyers — like giving a promising product a VIP pass through regulatory traffic, reducing time and risk to potential revenue.
Rare Pediatric Disease Designation regulatory
"FDA previously granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of JDM"
A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.
in vivo CAR-T platform medical
"agreement with WestGene Intended to Accelerate the Development of In Vivo CAR-T Platform"
Earnings Snapshot
Net income: $15.8 million
quarter ended June 30, 2026
Net income
$15.8 million
compared with $15.9 million for the three months ended June 30, 2025
Basic net income per share
$0.47
compared with $0.51 in the three months ended June 30, 2025
Research and development expenses
$20.4 million
up from $14.9 million for the three months ended June 30, 2025
General and administrative expenses
$8.7 million
up from $7.2 million for the three months ended June 30, 2025
Total revenues
$0
compared with $0.3 million (grant revenue) in the three months ended June 30, 2025
Cash, cash equivalents and restricted cash
$149.3 million
as of June 30, 2026
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Cartesian Therapeutics (RNAC) key financial results for Q2 2026?
Cartesian reported net income of $15.8 million for Q2 2026, or $0.47 basic EPS. Research and development expenses were $20.4 million, and general and administrative expenses were $8.7 million for the three months ended June 30, 2026.
How much cash and runway does Cartesian Therapeutics (RNAC) have as of June 30, 2026?
As of June 30, 2026, Cartesian held approximately $149.3 million in cash, cash equivalents and restricted cash. Together with its K2 HealthVentures credit facility, the company expects these resources to support planned operations into 2028, including multiple upcoming clinical readouts.
What is the status and timing of Cartesian Therapeutics (RNAC) Phase 3 AURORA trial?
The Phase 3 AURORA trial evaluates Descartes-08 in about 100 MG patients using six weekly outpatient infusions without preconditioning chemotherapy. Top-line data are expected in 1Q27, with a BLA filing planned for mid-2027 if results support it.
What are the key terms of the K2 HealthVentures credit facility for Cartesian Therapeutics (RNAC)?
Cartesian has a non-dilutive credit facility with K2 HealthVentures for up to $150 million. A first $50 million term loan funded in May 2026, with additional $25 million tranches in 2027 and 2028 tied to specified milestones, plus an optional $50 million tranche at K2HV’s discretion.
What is Cartesian Therapeutics (RNAC) partnership with WestGene and when is data expected?
Cartesian partnered with WestGene on an in vivo CAR-T platform using targeted lipid nanoparticles. A Phase 1 dose-escalation trial in myasthenia gravis is expected to start in 2H26, with in-human clinical data anticipated in the first half of 2027.
What is Descartes-08 and what regulatory designations has it received?
Descartes-08 is an autologous BCMA-targeted CAR-T therapy in development for generalized MG, myositis and pediatric autoimmune diseases. It has received Orphan Drug and Regenerative Medicine Advanced Therapy designations for MG, and Rare Pediatric Disease designation for juvenile dermatomyositis.
Which upcoming clinical milestones has Cartesian Therapeutics (RNAC) highlighted?
The company expects four key readouts over roughly the next year: Phase 3 AURORA MG data in 1Q27, subset data from the Phase 2 TRITON myositis trial in 1H27, Phase 1/2 HELIOS pediatric data in 1H27, and Phase 1 in vivo MG data in 1H27.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices)(Zip Code)
(301 ) 348-8698
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Cartesian Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Exhibit Description | |||||||
| 99.1 | Press release of Cartesian Therapeutics, Inc. issued on August 6, 2026. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CARTESIAN THERAPEUTICS, INC. | ||||||||
| Date: August 6, 2026 | By: | /s/ Carsten Brunn, Ph.D. | ||||||
| Carsten Brunn, Ph.D. | ||||||||
| President, Chief Executive Officer and Chairman of the Board | ||||||||
Exhibit 99.1
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27
Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27
Phase 1 in vivo trial in MG patients, in partnership with WestGene BioPharma (WestGene), expected to initiate in 2H26; clinical data expected in 1H27
Approximately $149.3 million cash, cash equivalents and restricted cash as of June 30, 2026, expected to support planned operations into 2028
Frederick, Md., August 6, 2026 (GLOBE NEWSWIRE) – Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026, and outlined recent business updates.
“This quarter was marked by significant progress as we secured a strategic partnership to explore an in vivo platform and executed a non-dilutive financing, enhancing our pipeline and extending cash runway. As we prepare for four expected clinical readouts over the next twelve months, including from our Phase 3 AURORA trial in patients with MG in the first quarter of 2027, these agreements further strengthen our emerging pipeline and financial position,” said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. “Our partnership with WestGene gives us an efficient, accelerated path to extend our payloads into in vivo delivery, with in-human clinical data expected in the first half of next year. While our top priority remains executing on our Phase 3 AURORA trial, our WestGene partnership is intended to create future optionality for Cartesian across MG and other autoimmune indications, with the potential to further enhance cell therapy delivery and shift the treatment paradigm. As we advance toward this next phase of growth, an extended cash runway into 2028, supported by up to $150 million of non-dilutive financing through a credit facility with K2 HealthVentures (“K2HV”), allows us to continue investing in precommercial readiness activities in parallel with clinical execution. We look forward to a robust set of near-term milestones ahead, each bringing us closer to addressing the significant unmet need for deep and durable treatments in autoimmune diseases.”
Pipeline Progress and Anticipated Milestones
•Phase 3 AURORA Trial of Descartes-08 in Participants with MG; Data Expected in 1Q27, with BLA Planned for Mid-2027. The randomized, double-blind, placebo-controlled Phase 3 AURORA trial is designed to assess Descartes-08, Cartesian’s autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T) versus placebo (1:1 randomization) administered as six once-weekly outpatient infusions without preconditioning chemotherapy in approximately 100 patients with acetylcholine receptor autoantibody positive (AChR Ab+) MG. The primary endpoint will assess the proportion of Descartes-08 participants with an improvement in MG Activities of Daily Living (MG-ADL) score of three points or more at Month 4 compared to placebo.
•Announced New Strategic Licensing Agreement with WestGene Intended to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases; Phase 1 Data Expected in 1H27. Cartesian has partnered with WestGene to conduct a Phase 1 dose-escalation trial of the mRNA used in Descartes-08 delivered via WestGene’s proprietary targeted lipid nanoparticles (tLNPs) in patients with MG. Intravenous infusions will be administered across multiple dose levels using a Bayesian Optimal Interval (BOIN) adaptive design with a comprehensive translational assessment package including clinical response measures. The program represents a novel in vivo approach to BCMA-directed T-cell engineering that, if successful, could eliminate the need for ex vivo manufacturing. Cartesian is also planning to advance multiple internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed T-cell engager (TCE) as part of its expanding mRNA payload portfolio. The WestGene partnership is designed to provide an efficient framework to move additional Cartesian payloads into human trials, extending the platform’s potential to generate clinical proof-of-concept data across multiple programs in several disease states. Under the terms of the agreement, WestGene received an upfront payment and is eligible to receive potential development and commercial based milestone payments. This clinical trial is expected to initiate in the second half of 2026 with in-human data expected in the first half of 2027.
•Phase 2 TRITON Trial in Myositis Remains on Track with Data from Subset of Patients Expected in 1H27 to Inform Path Forward to Pivotal Trial. The randomized, double-blind, placebo-controlled Phase 2 TRITON trial in myositis is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. The primary endpoint is to assess the safety and efficacy of Descartes-08 compared to placebo added to standard of care in participants with myositis. The Company plans to evaluate a subset of patients from the trial to determine the potential path to a pivotal trial in myositis.
•Phase 1/2 HELIOS Pediatric Trial of Descartes-08 in Autoimmune Diseases, Including JDM, Continues to Progress with Data Expected in 1H27. Enrollment remains ongoing in the Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including JDM. JDM is a rare pediatric autoimmune disorder marked by pathognomonic skin rash and muscle inflammation affecting multiple organ systems. The U.S. Food and Drug Administration (FDA) previously granted Rare Pediatric Disease Designation to Descartes-08 for the treatment of JDM.
Corporate Update
•Cash Runway Extended into 2028 with Up to $150 Million of Non-Dilutive Financing from K2HV Secured. Under the Company’s credit facility with K2HV, the first $50 million term loan was funded upon signing of the agreement in May 2026. The second $25 million term loan is expected to be available to be drawn between January 1, 2027 and December 1, 2027, subject to the Company’s achievement of specified clinical and financing milestones and the third $25 million term loan is expected to be available to be drawn between January 1, 2028 and June 1, 2028, subject to the Company’s achievement of specified approval and sales milestones. An additional $50 million tranche is available for draw at the Company’s option subject to K2HV’s discretion. The Company now anticipates current cash resources to support planned operations into 2028, including through four expected clinical data readouts and accelerated investment in precommercial activities.
Second Quarter 2026 Financial Results
•Cash, cash equivalents and restricted cash as of June 30, 2026 was $149.3 million, inclusive of the initial $50 million tranche of non-dilutive financing from K2HV and $19.3 million raised year to date after commissions and expenses through the Company’s at the market (ATM) offering program. The Company’s current cash resources on hand are expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial, into 2028.
•Research and development expenses were $20.4 million for the three months ended June 30, 2026, compared to $14.9 million for the three months ended June 30, 2025. The increase was primarily a result of increased expenses associated with the ongoing Phase 3 AURORA trial, partially offset by a decrease in stock-based compensation expenses and a decrease in expenses for early stage programs.
•General and administrative expenses were $8.7 million for the three months ended June 30, 2026, compared to $7.2 million for the three months ended June 30, 2025. The increase was primarily the result of higher professional and consulting fees.
•Net income was $15.8 million, or $0.47 net income per share allocable to common stockholders (basic), for the three months ended June 30, 2026, compared to net income of $15.9 million, or $0.51 net income per share allocable to common stockholders (basic), for the three months ended June 30, 2025.
About Descartes-08
Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous CAR-T product targeting BCMA in clinical development for generalized MG and myositis, specifically dermatomyositis and antisynthetase syndrome. In contrast to conventional DNA-based CAR T-cell therapies, Cartesian’s CAR-T administration is designed to not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG, and Rare Pediatric Disease Designation for the treatment of JDM.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Forward Looking Statements
Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the Company’s expected cash resources and cash runway, the availability and use of funds under the Company’s credit facility with K2HV, statements regarding the partnership and strategic licensing agreement between the Company and WestGene and the ability of the Company and WestGene to develop therapies, treat disease, extend mRNA payloads into in vivo delivery, the integration and complementary nature of the Company’s product candidates and WestGene’s lipid nanoparticles platform, the speed and efficiency of the development pathway for collaboration products between the Company and WestGene, the ability of the Company and its partnership with WestGene to generate clinical proof-of-concept data across multiple programs in several disease states, the ability of the Company and its partnership with WestGene to advance multiple internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE and the speed at which these constructs and TCE are developed, the ability of the Company’s product candidates to be administered in an outpatient setting or without the need for preconditioning lymphodepleting chemotherapy, the potential of Descartes-08, or any of the Company’s other product candidates to treat MG, juvenile MG, myositis, JDM, or any other disease, the anticipated timing or the outcome of ongoing and planned clinical trials, studies and data readouts, including the ongoing Phase 3 AURORA trial of Descartes-08 in MG, the ongoing Phase 2 TRITON trial of Descartes-08 in myositis, and the ongoing Phase 1/2 HELIOS pediatric trial of Descartes-08 in autoimmune diseases, including JDM, the anticipated timing or the outcome of the FDA’s review of the Company’s regulatory filings, including the number of trials that may be necessary in order to obtain marketing approval, the Company’s ability to conduct its clinical trials and preclinical studies, the timing or making of any regulatory filings, the anticipated timing or outcome of selection of developmental product candidates, the ability of the Company to enter into and maintain potential collaborations or partnerships, the novelty of treatment paradigms that the Company is able to develop, the potential of any therapies developed by the Company to fulfill unmet medical needs, and enrollment in the Company’s clinical trials and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including proof of concept trials, including uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial and whether results of early clinical trials will be indicative of the results of later clinical trials, the ability to predict results of studies performed on human beings based on results of studies performed on non-human subjects, the unproven approach of the Company’s technology, potential delays in enrollment of patients, undesirable side effects of the Company’s product candidates, political uncertainty, the Company’s reliance on third parties to conduct its clinical trials, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows, substantial fluctuation in the price of the Company’s common stock, risks related to geopolitical conflicts, pandemics, and macroeconomic impacts, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in other filings that the Company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any intention to update any forward-looking statements included in this press release, except as required by law.
Cartesian Therapeutics, Inc. and Subsidiaries
Consolidated Balance Sheets
(Amounts in thousands, except share data and par value)
| June 30, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 147,606 | $ | 125,139 | |||||||
| Accounts receivable | 196 | 1,115 | |||||||||
| Prepaid expenses and other current assets | 5,813 | 3,022 | |||||||||
| Total current assets | 153,615 | 129,276 | |||||||||
| Property and equipment, net | 11,311 | 12,185 | |||||||||
| Right-of-use assets, net | 5,124 | 5,601 | |||||||||
In-process research and development asset | 93,900 | 93,900 | |||||||||
| Goodwill | 48,163 | 48,163 | |||||||||
| Long-term restricted cash | 1,735 | 1,735 | |||||||||
| Long-term prepaid expenses and other assets | 4,780 | 5,551 | |||||||||
| Total assets | $ | 318,628 | $ | 296,411 | |||||||
| Liabilities and stockholders’ deficit | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 1,046 | $ | 1,288 | |||||||
| Accrued expenses and other current liabilities | 15,142 | 9,498 | |||||||||
| Lease liabilities | 4,197 | 4,151 | |||||||||
| Warrant liability | 165 | — | |||||||||
| Total current liabilities | 20,550 | 14,937 | |||||||||
| Lease liabilities, net of current portion | 6,805 | 8,525 | |||||||||
| Warrant liability, net of current portion | — | 141 | |||||||||
| Long-term debt, net | 52,851 | — | |||||||||
| Contingent value rights liability | 356,700 | 392,100 | |||||||||
| Deferred tax liabilities, net | 6,948 | 6,948 | |||||||||
| Total liabilities | 443,854 | 422,651 | |||||||||
| Stockholders’ deficit: | |||||||||||
Series A Preferred Stock, $0.0001 par value; 112,164.533 and 134,904.563 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 98,050.372 and 120,790.402 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — | |||||||||
Series B Preferred Stock, $0.0001 par value; 437,927 shares authorized as of June 30, 2026 and December 31, 2025; 437,927 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — | |||||||||
Preferred stock, $0.0001 par value; 9,449,908.467 and 9,427,168.437 shares authorized as of June 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — | |||||||||
Common stock, $0.0001 par value; 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 30,037,962 and 26,011,106 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 3 | 3 | |||||||||
| Additional paid-in capital | 725,165 | 700,706 | |||||||||
| Accumulated deficit | (845,786) | (822,373) | |||||||||
| Accumulated other comprehensive loss | (4,608) | (4,576) | |||||||||
| Total stockholders’ deficit | (125,226) | (126,240) | |||||||||
| Total liabilities and stockholders’ deficit | $ | 318,628 | $ | 296,411 | |||||||
Cartesian Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||||||
| Revenues: | ||||||||||||||||||||
| Collaboration and license | $ | — | $ | — | $ | — | $ | 400 | ||||||||||||
| Grant | — | 298 | 78 | 998 | ||||||||||||||||
| Total revenues | — | 298 | 78 | 1,398 | ||||||||||||||||
| Operating expenses: | ||||||||||||||||||||
| Research and development | 20,431 | 14,869 | 39,894 | 29,543 | ||||||||||||||||
| General and administrative | 8,724 | 7,240 | 15,838 | 15,555 | ||||||||||||||||
| Total operating expenses | 29,155 | 22,109 | 55,732 | 45,098 | ||||||||||||||||
| Operating loss | (29,155) | (21,811) | (55,654) | (43,700) | ||||||||||||||||
| Other income (expense): | ||||||||||||||||||||
| Interest income | 1,103 | 1,748 | 2,129 | 3,763 | ||||||||||||||||
| Interest expense | (852) | — | (852) | — | ||||||||||||||||
| (Loss) gain on change in fair value of warrant liability | (118) | 654 | (24) | 2,472 | ||||||||||||||||
| Loss on change in fair value of embedded derivative | (4,535) | — | (4,535) | — | ||||||||||||||||
| Gain on change in fair value of contingent value rights liability | 49,200 | 35,300 | 35,400 | 35,646 | ||||||||||||||||
| Other income (expense), net | 126 | (5) | 123 | (5) | ||||||||||||||||
| Total other income, net | 44,924 | 37,697 | 32,241 | 41,876 | ||||||||||||||||
| Net income (loss) | $ | 15,769 | $ | 15,886 | $ | (23,413) | $ | (1,824) | ||||||||||||
| Other comprehensive (loss) income: | ||||||||||||||||||||
| Foreign currency translation adjustment | (25) | 12 | (32) | 44 | ||||||||||||||||
| Total comprehensive income (loss) | $ | 15,744 | $ | 15,898 | $ | (23,445) | $ | (1,780) | ||||||||||||
| Net income (loss) | $ | 15,769 | $ | 15,886 | (23,413) | (1,824) | ||||||||||||||
| Less: Undistributed earnings allocable to participating securities | (2,049) | (2,628) | — | — | ||||||||||||||||
| Net income (loss) allocable to shares of common stock - basic and diluted | $ | 13,720 | $ | 13,258 | $ | (23,413) | $ | (1,824) | ||||||||||||
| Net income (loss) per share allocable to common stockholders: | ||||||||||||||||||||
| Basic | $ | 0.47 | $ | 0.51 | $ | (0.83) | $ | (0.07) | ||||||||||||
| Diluted | $ | 0.46 | $ | 0.50 | $ | (0.83) | $ | (0.07) | ||||||||||||
| Weighted-average common shares outstanding: | ||||||||||||||||||||
| Basic | 29,467,130 | 25,980,262 | 28,142,256 | 25,941,670 | ||||||||||||||||
| Diluted | 29,860,880 | 26,447,251 | 28,142,256 | 25,941,670 | ||||||||||||||||
Investor Contact
Megan LeDuc
Associate Director of Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com